Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients

M. Giusti, L. Mortara, N. Machello, E. Monti, G. Pera, M. Marenzana

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The goal of levo-thyroxine (L-T4) administration in differentiated thyroid cancer (DTC) is to suppress thyroid stimulating hormone (TSH) levels. The tolerability and efficacy of a new formulation of liquid L-T4 vs. the previous tablet formulation was evaluated in a cohort of 59 patients with cured DTC. The correlation between breakfast modality and therapy was also monitored. Hormonal and clinical evaluations were performed before and 70 days after patients were switched from tablet to liquid L-T4 formulation, without changes in daily dose. Breakfast habits were evaluated. The interval between L-T4 therapy and breakfast was recorded. Patient approval of L-T4 formulations was evaluated. 8% of patients dropped out owing to adverse events. The modality of L-T4 administration proved adequate under tablet and liquid formulation in 64% and 68% of patients who fully complied with the protocol. While significantly more patients found the tablet formulation more agreeable, at the end of the protocol subjective symptoms had diminished significantly and 73% requested to remain on the liquid formulation. No change in TSH, thyroid hormones or thyroglobulin was noted during the study. A balanced breakfast containing less than 4 g of alimentary fibre did not interfere with L-T4 therapy. Liquid L-T4 seems to be a valid alternative formulation in DTC patients, its initial dislike being outweighed by a significant reduction in subjective symptoms. Both tablet and liquid L-T4 therapy require monitoring over time. A continental breakfast containing less than 4 g of alimentary fibres seems to favour the absorption of L-T4, whether in tablet or liquid formulation.

Original languageEnglish
Pages (from-to)332-336
Number of pages5
JournalDrug Research
Volume65
Issue number6
DOIs
Publication statusPublished - Jul 14 2014

Fingerprint

Thyroxine
Thyroid Neoplasms
Breakfast
Tablets
Thyrotropin
Thyroglobulin
Therapeutics
Thyroid Hormones
Habits

Keywords

  • continental breakfast
  • differentiated thyroid cancer
  • liquid L-T4

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. / Giusti, M.; Mortara, L.; Machello, N.; Monti, E.; Pera, G.; Marenzana, M.

In: Drug Research, Vol. 65, No. 6, 14.07.2014, p. 332-336.

Research output: Contribution to journalArticle

Giusti, M, Mortara, L, Machello, N, Monti, E, Pera, G & Marenzana, M 2014, 'Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients', Drug Research, vol. 65, no. 6, pp. 332-336. https://doi.org/10.1055/s-0034-1384535
Giusti, M. ; Mortara, L. ; Machello, N. ; Monti, E. ; Pera, G. ; Marenzana, M. / Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. In: Drug Research. 2014 ; Vol. 65, No. 6. pp. 332-336.
@article{8c648a7f2a3c4e01ad6c51b8fb903e86,
title = "Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients",
abstract = "The goal of levo-thyroxine (L-T4) administration in differentiated thyroid cancer (DTC) is to suppress thyroid stimulating hormone (TSH) levels. The tolerability and efficacy of a new formulation of liquid L-T4 vs. the previous tablet formulation was evaluated in a cohort of 59 patients with cured DTC. The correlation between breakfast modality and therapy was also monitored. Hormonal and clinical evaluations were performed before and 70 days after patients were switched from tablet to liquid L-T4 formulation, without changes in daily dose. Breakfast habits were evaluated. The interval between L-T4 therapy and breakfast was recorded. Patient approval of L-T4 formulations was evaluated. 8{\%} of patients dropped out owing to adverse events. The modality of L-T4 administration proved adequate under tablet and liquid formulation in 64{\%} and 68{\%} of patients who fully complied with the protocol. While significantly more patients found the tablet formulation more agreeable, at the end of the protocol subjective symptoms had diminished significantly and 73{\%} requested to remain on the liquid formulation. No change in TSH, thyroid hormones or thyroglobulin was noted during the study. A balanced breakfast containing less than 4 g of alimentary fibre did not interfere with L-T4 therapy. Liquid L-T4 seems to be a valid alternative formulation in DTC patients, its initial dislike being outweighed by a significant reduction in subjective symptoms. Both tablet and liquid L-T4 therapy require monitoring over time. A continental breakfast containing less than 4 g of alimentary fibres seems to favour the absorption of L-T4, whether in tablet or liquid formulation.",
keywords = "continental breakfast, differentiated thyroid cancer, liquid L-T4",
author = "M. Giusti and L. Mortara and N. Machello and E. Monti and G. Pera and M. Marenzana",
year = "2014",
month = "7",
day = "14",
doi = "10.1055/s-0034-1384535",
language = "English",
volume = "65",
pages = "332--336",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "6",

}

TY - JOUR

T1 - Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients

AU - Giusti, M.

AU - Mortara, L.

AU - Machello, N.

AU - Monti, E.

AU - Pera, G.

AU - Marenzana, M.

PY - 2014/7/14

Y1 - 2014/7/14

N2 - The goal of levo-thyroxine (L-T4) administration in differentiated thyroid cancer (DTC) is to suppress thyroid stimulating hormone (TSH) levels. The tolerability and efficacy of a new formulation of liquid L-T4 vs. the previous tablet formulation was evaluated in a cohort of 59 patients with cured DTC. The correlation between breakfast modality and therapy was also monitored. Hormonal and clinical evaluations were performed before and 70 days after patients were switched from tablet to liquid L-T4 formulation, without changes in daily dose. Breakfast habits were evaluated. The interval between L-T4 therapy and breakfast was recorded. Patient approval of L-T4 formulations was evaluated. 8% of patients dropped out owing to adverse events. The modality of L-T4 administration proved adequate under tablet and liquid formulation in 64% and 68% of patients who fully complied with the protocol. While significantly more patients found the tablet formulation more agreeable, at the end of the protocol subjective symptoms had diminished significantly and 73% requested to remain on the liquid formulation. No change in TSH, thyroid hormones or thyroglobulin was noted during the study. A balanced breakfast containing less than 4 g of alimentary fibre did not interfere with L-T4 therapy. Liquid L-T4 seems to be a valid alternative formulation in DTC patients, its initial dislike being outweighed by a significant reduction in subjective symptoms. Both tablet and liquid L-T4 therapy require monitoring over time. A continental breakfast containing less than 4 g of alimentary fibres seems to favour the absorption of L-T4, whether in tablet or liquid formulation.

AB - The goal of levo-thyroxine (L-T4) administration in differentiated thyroid cancer (DTC) is to suppress thyroid stimulating hormone (TSH) levels. The tolerability and efficacy of a new formulation of liquid L-T4 vs. the previous tablet formulation was evaluated in a cohort of 59 patients with cured DTC. The correlation between breakfast modality and therapy was also monitored. Hormonal and clinical evaluations were performed before and 70 days after patients were switched from tablet to liquid L-T4 formulation, without changes in daily dose. Breakfast habits were evaluated. The interval between L-T4 therapy and breakfast was recorded. Patient approval of L-T4 formulations was evaluated. 8% of patients dropped out owing to adverse events. The modality of L-T4 administration proved adequate under tablet and liquid formulation in 64% and 68% of patients who fully complied with the protocol. While significantly more patients found the tablet formulation more agreeable, at the end of the protocol subjective symptoms had diminished significantly and 73% requested to remain on the liquid formulation. No change in TSH, thyroid hormones or thyroglobulin was noted during the study. A balanced breakfast containing less than 4 g of alimentary fibre did not interfere with L-T4 therapy. Liquid L-T4 seems to be a valid alternative formulation in DTC patients, its initial dislike being outweighed by a significant reduction in subjective symptoms. Both tablet and liquid L-T4 therapy require monitoring over time. A continental breakfast containing less than 4 g of alimentary fibres seems to favour the absorption of L-T4, whether in tablet or liquid formulation.

KW - continental breakfast

KW - differentiated thyroid cancer

KW - liquid L-T4

UR - http://www.scopus.com/inward/record.url?scp=84930417373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930417373&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1384535

DO - 10.1055/s-0034-1384535

M3 - Article

C2 - 25020105

AN - SCOPUS:84930417373

VL - 65

SP - 332

EP - 336

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 6

ER -